Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E J Small

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancerP W Kantoff, S Halabi, D A Farmer, et al.
Urology|August 15, 2001
Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomyG D Grossfeld, E J Small, D P Lubeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survivalE J Small, A McMillan, M Meyer, et al.
Blood|January 1, 1985
A monoclonal antibody that inhibits activation of human Hageman factor (factor XII)E J Small, J A Katzmann, R P Tracy, et al.
Prostate Cancer and Prostatic Diseases|June 25, 2014
Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-TE J Small, C S Higano, P W Kantoff, et al.
Cancer|February 19, 2000
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181N A Dawson, M Conaway, S Halabi, et al.
Cancer|June 1, 1994
A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinomaE J Small, J W Frye, M J Wilkinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2000
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cellsE J Small, P Fratesi, D M Reese, et al.
Cancer Research|June 11, 1999
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonistM E Taplin, G J Bubley, Y J Ko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480D J George, S Halabi, T F Shepard, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancerP W Kantoff, S Halabi, D A Farmer, et al.
Urology|August 15, 2001
Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomyG D Grossfeld, E J Small, D P Lubeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survivalE J Small, A McMillan, M Meyer, et al.
Blood|January 1, 1985
A monoclonal antibody that inhibits activation of human Hageman factor (factor XII)E J Small, J A Katzmann, R P Tracy, et al.
Prostate Cancer and Prostatic Diseases|June 25, 2014
Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-TE J Small, C S Higano, P W Kantoff, et al.
Cancer|February 19, 2000
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181N A Dawson, M Conaway, S Halabi, et al.
Cancer|June 1, 1994
A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinomaE J Small, J W Frye, M J Wilkinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2000
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cellsE J Small, P Fratesi, D M Reese, et al.
Cancer Research|June 11, 1999
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonistM E Taplin, G J Bubley, Y J Ko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480D J George, S Halabi, T F Shepard, et al.
Pageof 9